{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:51:18Z","timestamp":1791150678875,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,7,27]],"date-time":"2004-07-27T00:00:00Z","timestamp":1090886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1038\/sj.bjc.6602052","type":"journal-article","created":{"date-parts":[[2004,7,28]],"date-time":"2004-07-28T08:30:38Z","timestamp":1091003438000},"page":"803-810","source":"Crossref","is-referenced-by-count":39,"title":["Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells"],"prefix":"10.1038","volume":"91","author":[{"given":"A-M","family":"Forsea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Riebeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C E","family":"Orfanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C C","family":"Geilen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,7,27]]},"reference":[{"key":"BF6602052_CR1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/sj.leu.2400892","volume":"12","author":"A Aparicio","year":"1998","unstructured":"Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A (1998) In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12: 220\u2013229","journal-title":"Leukemia"},{"key":"BF6602052_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0304-3835(01)00412-8","volume":"165","author":"S Aznar","year":"2001","unstructured":"Aznar S, Lacal JC (2001) Rho signals to cell growth and apoptosis. Cancer Lett 165: 1\u201310","journal-title":"Cancer Lett"},{"key":"BF6602052_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0092-8674(00)00115-X","volume":"103","author":"D Bar-Sagi","year":"2000","unstructured":"Bar-Sagi D, Hall A (2000) Ras and Rho GTPases: a family reunion. Cell 103: 227\u2013238","journal-title":"Cell"},{"key":"BF6602052_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1124\/mol.56.1.131","volume":"56","author":"HL Benford","year":"1999","unstructured":"Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ (1999) Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56: 131\u2013140","journal-title":"Mol Pharmacol"},{"key":"BF6602052_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S8756-3282(01)00412-4","volume":"28","author":"HL Benford","year":"2001","unstructured":"Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ (2001) Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28: 465\u2013473","journal-title":"Bone"},{"key":"BF6602052_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/j.1552-4604.1997.tb04304.x","volume":"37","author":"JR Berenson","year":"1997","unstructured":"Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, Seaman JJ (1997) Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 37: 285\u2013290","journal-title":"J Clin Pharmacol"},{"key":"BF6602052_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1006\/abbi.1999.1502","volume":"373","author":"JD Bergstrom","year":"2000","unstructured":"Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G (2000) Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373: 231\u2013241","journal-title":"Arch Biochem Biophys"},{"key":"BF6602052_CR8","first-page":"2949","volume":"60","author":"S Boissier","year":"2000","unstructured":"Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949\u20132954","journal-title":"Cancer Res"},{"key":"BF6602052_CR9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/35020106","volume":"406","author":"EA Clark","year":"2000","unstructured":"Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532\u2013535","journal-title":"Nature"},{"key":"BF6602052_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1053\/sonc.2002.34878","volume":"29","author":"P Clezardin","year":"2002","unstructured":"Clezardin P (2002) The antitumor potential of bisphosphonates. Semin Oncol 29: 33\u201342","journal-title":"Semin Oncol"},{"key":"BF6602052_CR11","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1359\/jbmr.2000.15.8.1467","volume":"15","author":"FP Coxon","year":"2000","unstructured":"Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15: 1467\u20131476","journal-title":"J Bone Miner Res"},{"key":"BF6602052_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/BF02555856","volume":"49","author":"PT Daley-Yates","year":"1991","unstructured":"Daley-Yates PT, Dodwell DJ, Pongchaidecha M, Coleman RE, Howell A (1991) The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcif Tissue Int 49: 433\u2013435","journal-title":"Calcif Tissue Int"},{"key":"BF6602052_CR13","first-page":"235","volume":"296","author":"JE Dunford","year":"2001","unstructured":"Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure\u2013activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235\u2013242","journal-title":"J Pharmacol Exp Ther"},{"key":"BF6602052_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1053\/sonc.2002.31534","volume":"29","author":"RS Finley","year":"2002","unstructured":"Finley RS (2002) Bisphosphonates in the treatment of bone metastases. Semin Oncol 29: 132\u2013138","journal-title":"Semin Oncol"},{"key":"BF6602052_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/bcr414","volume":"4","author":"H Fleisch","year":"2002","unstructured":"Fleisch H (2002) Development of bisphosphonates. Breast Cancer Res 4: 30\u201334","journal-title":"Breast Cancer Res"},{"key":"BF6602052_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/07853899708998743","volume":"29","author":"HA Fleisch","year":"1997","unstructured":"Fleisch HA (1997) Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 29: 55\u201362","journal-title":"Ann Med"},{"key":"BF6602052_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B","volume":"81","author":"G Fritz","year":"1999","unstructured":"Fritz G, Just I, Kaina B (1999) Rho GTPases are over-expressed in human tumors. Int J Cancer 81: 682\u2013687","journal-title":"Int J Cancer"},{"key":"BF6602052_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0093-7754(01)90259-3","volume":"28","author":"JR Green","year":"2001","unstructured":"Green JR (2001) Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol 28: 4\u201310","journal-title":"Semin Oncol"},{"key":"BF6602052_CR19","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/cncr.11128","volume":"97","author":"JR Green","year":"2003","unstructured":"Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97: 840\u2013847","journal-title":"Cancer"},{"key":"BF6602052_CR20","first-page":"4418","volume":"61","author":"T Hiraga","year":"2001","unstructured":"Hiraga T, Williams PJ, Mundy GR, Yoneda T (2001) The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61: 4418\u20134424","journal-title":"Cancer Res"},{"key":"BF6602052_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1074\/jbc.272.1.13","volume":"272","author":"A Hirai","year":"1997","unstructured":"Hirai A, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Tatsuno I, Oeda T, Tahara K, Terano T, Narumiya S, Kohn LD, Saito Y (1997) Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 272: 13\u201316","journal-title":"J Biol Chem"},{"key":"BF6602052_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0898-6568(03)00007-X","volume":"15","author":"T Iguchi","year":"2003","unstructured":"Iguchi T, Miyakawa Y, Yamamoto K, Kizaki M, Ikeda Y (2003) Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal 15: 719\u2013727","journal-title":"Cell Signal"},{"key":"BF6602052_CR23","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","volume":"84","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126\u20131134","journal-title":"Br J Cancer"},{"key":"BF6602052_CR24","first-page":"2602","volume":"61","author":"MV Lee","year":"2001","unstructured":"Lee MV, Fong EM, Singer FR, Guenette RS (2001) Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602\u20132608","journal-title":"Cancer Res"},{"key":"BF6602052_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","volume":"13","author":"SP Luckman","year":"1998","unstructured":"Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581\u2013589","journal-title":"J Bone Miner Res"},{"key":"BF6602052_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1006\/excr.1999.4608","volume":"252","author":"S Naderi","year":"1999","unstructured":"Naderi S, Blomhoff R, Myklebust J, Smeland EB, Erikstein B, Norum KR, Blomhoff HK (1999) Lovastatin inhibits G1\/S transition of normal human B-lymphocytes independent of apoptosis. Exp Cell Res 252: 144\u2013153","journal-title":"Exp Cell Res"},{"key":"BF6602052_CR27","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/01.ju.0000070685.34760.5f","volume":"170","author":"GM Oades","year":"2003","unstructured":"Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW (2003) Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170: 246\u2013252","journal-title":"J Urol"},{"key":"BF6602052_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/28425","volume":"394","author":"MF Olson","year":"1998","unstructured":"Olson MF, Paterson HF, Marshall CJ (1998) Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1\/Cip1. Nature 394: 295\u2013299","journal-title":"Nature"},{"key":"BF6602052_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/bcr415","volume":"4","author":"SS Padalecki","year":"2002","unstructured":"Padalecki SS, Guise TA (2002) Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Res 4: 35\u201341","journal-title":"Breast Cancer Res"},{"key":"BF6602052_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0304-3835(01)00528-6","volume":"171","author":"K Pruitt","year":"2001","unstructured":"Pruitt K, Der CJ (2001) Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 171: 1\u201310","journal-title":"Cancer Lett"},{"key":"BF6602052_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/mol.59.2.193","volume":"59","author":"AA Reszka","year":"2001","unstructured":"Reszka AA, Halasy-Nagy J, Rodan GA (2001) Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 59: 193\u2013202","journal-title":"Mol Pharmacol"},{"key":"BF6602052_CR32","doi-asserted-by":"publisher","first-page":"34967","DOI":"10.1074\/jbc.274.49.34967","volume":"274","author":"AA Reszka","year":"1999","unstructured":"Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA (1999) Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 274: 34967\u201334973","journal-title":"J Biol Chem"},{"key":"BF6602052_CR33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/sj.bjc.6600476","volume":"87","author":"C Riebeling","year":"2002","unstructured":"Riebeling C, Forsea AM, Raisova M, Orfanos CE, Geilen CC (2002) The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer 87: 366\u2013371","journal-title":"Br J Cancer"},{"key":"BF6602052_CR34","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1006\/bbrc.1996.1113","volume":"224","author":"MJ Rogers","year":"1996","unstructured":"Rogers MJ, Brown RJ, Hodkin V, Blackburn GM, Russell RG, Watts DJ (1996) Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 224: 863\u2013869","journal-title":"Biochem Biophys Res Commun"},{"key":"BF6602052_CR35","doi-asserted-by":"publisher","first-page":"73S","DOI":"10.1016\/S8756-3282(99)00070-8","volume":"24","author":"MJ Rogers","year":"1999","unstructured":"Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, Auriola S, Chilton KM, Russell RG (1999) Molecular mechanisms of action of bisphosphonates. Bone 24: 73S\u201379S","journal-title":"Bone"},{"key":"BF6602052_CR36","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","volume":"88","author":"MJ Rogers","year":"2000","unstructured":"Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88: 2961\u20132978","journal-title":"Cancer"},{"key":"BF6602052_CR37","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/sj.bjc.6600297","volume":"86","author":"SG Senaratne","year":"2002","unstructured":"Senaratne SG, Mansi JL, Colston KW (2002) The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 86: 1479\u20131486","journal-title":"Br J Cancer"},{"key":"BF6602052_CR38","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","volume":"82","author":"SG Senaratne","year":"2000","unstructured":"Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459\u20131468","journal-title":"Br J Cancer"},{"key":"BF6602052_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00008390-199902000-00007","volume":"9","author":"L Serrone","year":"1999","unstructured":"Serrone L, Hersey P (1999) The chemoresistance of human malignant melanoma: an update. Melanoma Res 9: 51\u201358","journal-title":"Melanoma Res"},{"key":"BF6602052_CR40","first-page":"5294","volume":"58","author":"CM Shipman","year":"1998","unstructured":"Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ (1998) The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58: 5294\u20135297","journal-title":"Cancer Res"},{"key":"BF6602052_CR41","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1046\/j.1365-2141.1997.2713086.x","volume":"98","author":"CM Shipman","year":"1997","unstructured":"Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 98: 665\u2013672","journal-title":"Br J Haematol"},{"key":"BF6602052_CR42","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/028418600750063587","volume":"39","author":"CM Shipman","year":"2000","unstructured":"Shipman CM, Rogers MJ, Vanderkerken K, Van Camp B, Graham R, Russell G, Croucher PI (2000) Bisphosphonates \u2013 mechanisms of action in multiple myeloma. Acta Oncol 39: 829\u2013835","journal-title":"Acta Oncol"},{"key":"BF6602052_CR43","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1038\/sj.onc.1206454","volume":"22","author":"MS Soengas","year":"2003","unstructured":"Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3138\u20133151","journal-title":"Oncogene"},{"key":"BF6602052_CR44","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/00001813-200106000-00007","volume":"12","author":"J Sonnemann","year":"2001","unstructured":"Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F (2001) The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 12: 459\u2013465","journal-title":"Anticancer Drugs"},{"key":"BF6602052_CR45","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S8756-3282(01)00589-0","volume":"29","author":"S Suri","year":"2001","unstructured":"Suri S, Monkkonen J, Taskinen M, Pesonen J, Blank MA, Phipps RJ, Rogers MJ (2001) Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 29: 336\u2013343","journal-title":"Bone"},{"key":"BF6602052_CR46","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1006\/bbrc.2001.6289","volume":"290","author":"K Thompson","year":"2002","unstructured":"Thompson K, Dunford JE, Ebetino FH, Rogers MJ (2002) Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem Biophys Res Commun 290: 869\u2013873","journal-title":"Biochem Biophys Res Commun"},{"key":"BF6602052_CR47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1006\/bbrc.1999.0224","volume":"255","author":"E van Beek","year":"1999","unstructured":"van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S (1999) Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase\/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255: 491\u2013494","journal-title":"Biochem Biophys Res Commun"},{"key":"BF6602052_CR48","doi-asserted-by":"publisher","first-page":"27224","DOI":"10.1074\/jbc.272.43.27224","volume":"272","author":"A Vogt","year":"1997","unstructured":"Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM (1997) The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0\/G1 and induces p21(WAF1\/CIP1\/SDI1) in a p53-independent manner. J Biol Chem 272: 27224\u201327229","journal-title":"J Biol Chem"},{"key":"BF6602052_CR49","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ncb1101-950","volume":"3","author":"CF Welsh","year":"2001","unstructured":"Welsh CF, Roovers K, Villanueva J, Liu Y, Schwartz MA, Assoian RK (2001) Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat Cell Biol 3: 950\u2013957","journal-title":"Nat Cell Biol"},{"key":"BF6602052_CR50","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1021\/jm020819i","volume":"45","author":"L Widler","year":"2002","unstructured":"Widler L, Jaeggi KA, Glatt M, Muller K, Bachmann R, Bisping M, Born AR, Cortesi R, Guiglia G, Jeker H, Klein R, Ramseier U, Schmid J, Schreiber G, Seltenmeyer Y, Green JR (2002) Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 45: 3721\u20133738","journal-title":"J Med Chem"},{"key":"BF6602052_CR51","doi-asserted-by":"publisher","first-page":"11025","DOI":"10.1074\/jbc.273.18.11025","volume":"273","author":"T Wieder","year":"1998","unstructured":"Wieder T, Orfanos CE, Geilen CC (1998) Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J Biol Chem 273: 11025\u201311031","journal-title":"J Biol Chem"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602052","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:11:23Z","timestamp":1684411883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,27]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["BF6602052"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602052","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,27]]}}}